|
1
|
Lin X, Kang K, Chen P, Zheng Z, Li G,
Xiong W, Yi M and Xiang B: Regulatory mechanisms of PD-1/PD-L1 in
cancers. Mol Cancer. 23(108)2024.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Pipitone RM, Lupo G, Zito R, Javed A,
Petta S, Pennisi G and Grimaudo S: The PD-1/PD-L1 axis in the
biology of MASLD. Int J Mol Sci. 25(3671)2024.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Liu J, Chen Z, Li Y, Zhao W, Wu J and
Zhang Z: PD-1/PD-L1 checkpoint inhibitors in tumor immunotherapy.
Front Pharmacol. 12(731798)2021.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Yi M, Li T, Niu M, Mei Q, Zhao B, Chu Q,
Dai Z and Wu K: Exploiting innate immunity for cancer
immunotherapy. Mol Cancer. 22(187)2023.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Tang Q, Chen Y, Li X, Long S, Shi Y, Yu Y,
Wu W, Han L and Wang S: The role of PD-1/PD-L1 and application of
immune-checkpoint inhibitors in human cancers. Front Immunol.
13(964442)2022.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Gao W, Liu S, Wu Y, Wei W, Yang Q, Li W,
Chen H, Luo A, Wang Y and Liu Z: Enhancer demethylation-regulated
gene score identified molecular subtypes, inspiring immunotherapy
or CDK4/6 inhibitor therapy in oesophageal squamous cell carcinoma.
EBioMedicine. 105(105177)2024.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Wood GE, Meyer C, Petitprez F and D'Angelo
SP: Immunotherapy in sarcoma: Current data and promising
strategies. Am Soc Clin Oncol Educ Book. 44(e432234)2024.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Martin-Broto J, Hindi N and Moura DS:
Combination treatment with PD1/PDL-1 inhibitors for sarcomas: State
of the art, next questions. Curr Opin Oncol. 36:269–275.
2024.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Anastasiou M, Kyriazoglou A, Kotsantis I,
Economopoulou P, Kyrkasiadou M, Giannopoulou A, Kosmidou A, Smerdi
D, Moutafi M, Gavrielatou N and Psyrri A: Immune checkpoint
inhibitors in sarcomas: A systematic review. Immunooncol Technol.
20(100407)2023.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Dong H, Strome SE, Salomao DR, Tamura H,
Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, et al:
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential
mechanism of immune evasion. Nat Med. 8:793–800. 2002.PubMed/NCBI View
Article : Google Scholar
|
|
11
|
Hashimoto K, Nishimura S and Akagi M:
Characterization of PD-1/PD-L1 immune checkpoint expression in
osteosarcoma. Diagnostics (Basel). 10(528)2020.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Paydas S, Bagir EK, Deveci MA and Gonluses
G: Clinical and prognostic significance of PD-1 and PD-L1
expression in sarcomas. Med Oncol. 33(93)2016.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Torabi A, Amaya CN, Wians FH Jr and Bryan
BA: PD-1 and PD-L1 expression in bone and soft tissue sarcomas.
Pathology. 49:506–513. 2017.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Orth MF, Buecklein VL, Kampmann E,
Subklewe M, Noessner E, Cidre-Aranaz F, Romero-Pérez L, Wehweck FS,
Lindner L, Issels R, et al: A comparative view on the expression
patterns of PD-L1 and PD-1 in soft tissue sarcomas. Cancer Immunol
Immunother. 69:1353–1362. 2020.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Miyake M, Oda Y, Nishimura N, Morizawa Y,
Ohnishi S, Hatakeyama K, Fujii T, Hori S, Gotoh D, Nakai Y, et al:
Integrative assessment of clinicopathological parameters and the
expression of PD L1, PD L2 and PD 1 in tumor cells of
retroperitoneal sarcoma. Oncol Lett. 20(190)2020.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Boxberg M, Steiger K, Lenze U, Rechl H,
von Eisenhart-Rothe R, Wörtler K, Weichert W, Langer R and Specht
K: PD-L1 and PD-1 and characterization of tumor-infiltrating
lymphocytes in high grade sarcomas of soft tissue–prognostic
implications and rationale for immunotherapy. Oncoimmunology.
7(e1389366)2018.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Hashimoto K, Nishimura S, Ito T and Akagi
M: Characterization of PD-1/PD-L1 immune checkpoint expression in
soft tissue sarcomas. Eur J Histochem. 65(3203)2021.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Kim C, Kim EK, Jung H, Chon HJ, Han JW,
Shin KH, Hu H, Kim KS, Choi YD, Kim S, et al: Prognostic
implications of PD-L1 expression in patients with soft tissue
sarcoma. BMC Cancer. 18:1–9. 2018.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Guo J, Li YM, Guo H, Hao DP, Xu JX, Huang
CC, Han HW, Hou F, Yang SF, Cui JL and Wang HX: Parallel CNN-deep
learning clinical-imaging signature for assessing pathologic grade
and prognosis of soft tissue sarcoma patients. J Magn Reson
Imaging. 61:807–819. 2024.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Hashimoto K, Nishimura S, Shinyashiki Y,
Ito T, Tanaka H, Ohtani K, Kakinoki R and Akagi M: PD-1, PD-L1,
NY-ESO-1, and MAGE-A4 expression in cutaneous angiosarcoma: A case
report. Medicine (Baltimore). 101(e29621)2022.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Hashimoto K, Nishimura S, Ito T, Kakinoki
R and Akagi M: Immunohistochemical expression and
clinicopathological assessment of PD-1, PD-L1, NY-ESO-1, and
MAGE-A4 expression in highly aggressive soft tissue sarcomas. Eur J
Histochem. 66(3393)2022.PubMed/NCBI View Article : Google Scholar
|
|
22
|
D'Angelo SP, Mahoney MR, Van Tine BA,
Atkins J, Milhem MM, Jahagirdar BN, Antonescu CR, Horvath E, Tap
WD, Schwartz GK and Streicher H: Nivolumab with or without
ipilimumab treatment for metastatic sarcoma (Alliance A091401): Two
open-label, non-comparative, randomized, phase 2 trials. Lancet
Oncol. 19:416–426. 2018.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Yildirim AN, Akyurek M, Okay E,
Zenginkinet T, Iyetin Y and Ozkan K: Programmed cell death ligand-1
(PD-L1) expression in desmoid tumors: A retrospective study. Eur
Rev Med Pharmacol Sci. 27:5223–5229. 2023.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Hashimoto K, Nishimura S, Shinyashiki Y,
Ito T, Kakinoki R and Akagi M: Clinicopathological assessment of
PD-1-comp/PD-L1 immune checkpoint expression in desmoid tumors. Eur
J Histochem. 67(3688)2023.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Young RJ, Brown NJ, Reed MW, Hughes D and
Woll PJ: Angiosarcoma. Lancet Oncol. 11:983–991. 2010.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Ai L, Xu A and Xu J: Roles of PD-1/PD-L1
pathway: Signaling, cancer, and beyond. Adv Exp Med Biol.
1248:33–59. 2020.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Lee JB, Ahn BC, Kim SH, Lee YH, Han JW,
Jeon MK, Kim SH and Kim HS: Prognostic implications of PD-L1
expression in patients with angiosarcoma. Future Sci OA.
7(FSO691)2021.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Shimizu A, Kaira K, Okubo Y, Utsumi D,
Yasuda M, Asao T, Nishiyama M, Takahashi K and Ishikawa O: Positive
PD-L1 expression predicts worse outcome in cutaneous angiosarcoma.
J Glob Oncol. 3:360–369. 2016.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Wen W, Zhang Y, Zhang H and Chen Y:
Clinical outcomes of PD-1/PD-L1 inhibitors in patients with
advanced hepatocellular carcinoma: A systematic review and
meta-analysis. J Cancer Res Clin Oncol. 149:969–978.
2023.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Tawbi HA, Burgess M, Bolejack V, Van Tine
BA, Schuetze SM, Hu J, D'Angelo S, Attia S, Riedel RF, Priebat DA,
et al: Pembrolizumab in advanced soft-tissue sarcoma and bone
sarcoma (SARC028): A multicentre, two-cohort, single-arm,
open-label, phase 2 trial. Lancet Oncol. 18:1493–1501.
2017.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Nowicki TS, Akiyama R, Huang RR, Shintaku
IP, Wang X, Tumeh PC, Singh A, Chmielowski B, Denny C, Federman N
and Ribas A: Infiltration of CD8 T cells and expression of PD-1 and
PD-L1 in synovial sarcoma. Cancer Immunol Res. 5:118–126.
2017.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Huang Q, Wu X, Wang Z, Chen X, Wang L, Lu
Y, Xiong D, Liu Q, Tian Y, Lin H, et al: The primordial
differentiation of tumor-specific memory CD8+ T cells as bona fide
responders to PD-1/PD-L1 blockade in draining lymph nodes. Cell.
185:4049–4066.e25. 2022.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Martin AM, Nirschl TR, Nirschl CJ,
Francica BJ, Kochel CM, van Bokhoven A, Meeker AK, Lucia MS, Anders
RA, Demarzo AM and Drake CG: Paucity of PD-L1 expression in
prostate cancer: Innate and adaptive immune resistance. Prostate
Cancer Prostatic Dis. 18:325–332. 2015.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Chen L and Han X: Anti-PD-1/PD-L1 therapy
of human cancer: Past, present, and future. J Clin Invest.
125:3384–3391. 2015.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Topalian SL, Hodi FS, Brahmer JR,
Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD,
Sosman JA, Atkins MB, et al: Safety, activity, and immune
correlates of anti-PD-1 antibody in cancer. N Engl J Med.
366:2443–2454. 2012.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ,
Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al:
Safety and activity of anti-PD-L1 antibody in patients with
advanced cancer. N Engl J Med. 366:2455–2465. 2012.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Italiano A, Bellera C and D'Angelo S:
PD1/PD-L1 targeting in advanced soft-tissue sarcomas: A pooled
analysis of phase II trials. J Hematol Oncol. 13(55)2020.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Somaiah N, Conley AP, Parra ER, Lin H,
Amini B, Soto LS, Salazar R, Barreto C, Chen H, Gite S, et al:
Durvalumab plus tremelimumab in advanced or metastatic soft tissue
and bone sarcomas: A single-centre phase 2 trial. Lancet Oncol.
23:1156–1166. 2022.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Gordon EM, Chawla SP, Tellez WA, Younesi
E, Thomas S, Chua-Alcala VS, Chomoyan H, Valencia C, Brigham DA,
Moradkhani A, et al: SAINT: A phase I/Expanded phase II study using
safe amounts of ipilimumab, nivolumab and trabectedin as first-line
treatment of advanced soft tissue sarcoma. Cancers (Basel).
15(906)2023.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Saif A, Verbus EA, Sarvestani AL, Teke ME,
Lambdin J, Hernandez JM and Kirsch DG: A randomized trial of
pembrolizumab & radiotherapy versus radiotherapy in high-risk
soft tissue sarcoma of the extremity (SU2C-SARC032). Ann Surg
Oncol. 30:683–685. 2023.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Liao Z, Teng J, Li T, Liu H, Li T, Zhang
C, Xing R, Teng S, Yang Y, Zhao J, et al: Evaluation of the
efficacy and safety of immunotherapy in sarcoma: A two-center
study. Front Immunol. 15(1292325)2024.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Babatunde O, Rosenbaum E, Kelly CM,
Desir-Camille R, Keohan ML, Banks L, Avutu V, Chan J, Reed D,
Gounder M, et al: 1752P A retrospective single-center study of
outcomes to immune checkpoint blockade-based therapy in
leiomyosarcoma. Ann Oncol. 35(S1045)2024.
|
|
43
|
Sonpavde GP, Grivas P, Lin Y, Hennessy D
and Hunt JD: Immune-related adverse events with PD-1 versus PD-L1
inhibitors: A meta-analysis of 8730 patients from clinical trials.
Future Oncol. 17:2545–2558. 2021.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Baxi S, Yang A, Gennarelli RL, Khan N,
Wang Z, Boyce L and Korenstein D: Immune-related adverse events for
anti-PD-1 and anti-PD-L1 drugs: Systematic review and
meta-analysis. BMJ. 360(k793)2018.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Liu X, Shi Y, Zhang D, Zhou Q, Liu J, Chen
M, Xu Y, Zhao J, Zhong W and Wang M: Risk factors for
immune-related adverse events: What have we learned and what lies
ahead? Biomark Res. 9(79)2021.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Kalinich M, Murphy W, Wongvibulsin S,
Pahalyants V, Yu KH, Lu C, Wang F, Zubiri L, Naranbhai V, Gusev A,
et al: Prediction of severe immune-related adverse events requiring
hospital admission in patients on immune checkpoint inhibitors:
Study of a population level insurance claims database from the USA.
J Immunother Cancer. 9(e001935)2021.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Schneider BJ, Naidoo J, Santomasso BD,
Lacchetti C, Adkins S, Anadkat M, Atkins MB, Brassil KJ, Caterino
JM, Chau J, et al: Management of immune-related adverse events in
patients treated with immune checkpoint inhibitor therapy: ASCO
guideline update. J Clin Oncol. 39:4073–4126. 2021.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Postow MA, Sidlow R and Hellmann MD:
Immune-related adverse events associated with immune checkpoint
blockade. N Engl J Med. 378:158–168. 2018.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Wang DY, Salem JE, Cohen JV, Chandra S,
Menzer C, Ye F, Zhao S, Das S, Beckermann KE, Ha L, et al: Fatal
toxic effects associated with immune checkpoint inhibitors: A
systematic review and meta-analysis. JAMA Oncol. 4:1721–1728.
2018.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Yi M, Zheng X, Niu M, Zhu S, Ge H and Wu
K: Combination strategies with PD-1/PD-L1 blockade: Current
advances and future directions. Mol Cancer. 21(28)2022.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Gandhi L, Rodríguez-Abreu D, Gadgeel S,
Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ,
Powell SF, et al: Pembrolizumab plus chemotherapy in metastatic
non-small-cell lung cancer. N Engl J Med. 378:2078–2092.
2018.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Lynch MM, Alexiev BA, Schroeder BA and
Pollack SM: Combinations of chemotherapy and PD-1/PD-L1 inhibitors
in sarcoma. Curr Treat Options Oncol. 23:1861–1876. 2022.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Dovedi SJ, Adlard AL, Lipowska-Bhalla G,
McKenna C, Jones S, Cheadle EJ, Stratford IJ, Poon E, Morrow M,
Steward R, et al: Acquired resistance to fractionated radiotherapy
can be overcome by concurrent PD-L1 blockade. Cancer Res.
74:5458–5468. 2014.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Patel KR, Martinez A, Stahl JM, Logan SJ,
Perricone AJ, Ferris MJ, Buchwald ZS, Chowdhary M, Delman KA,
Monson DK, et al: Increase in PD-L1 expression after pre-operative
radiotherapy for soft tissue sarcoma. Oncoimmunology.
7(e1442168)2018.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Katsuki S, Takahashi Y, Tamari K, Minami
K, Takenaka W, Ibuki Y, Yamamoto J, Tatekawa S, Hayashi K, Seo Y,
et al: Radiation therapy enhances systemic antitumor efficacy in
PD-L1 therapy regardless of sequence of radiation in murine
osteosarcoma. PLoS One. 17(e0271205)2022.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Wolchok JD, Kluger H, Callahan MK, Postow
MA, Rizvi NJ, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K,
et al: Nivolumab plus ipilimumab in advanced melanoma. N Engl J
Med. 369:122–133. 2013.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Huang S, Zheng G and Yang K: Neoadjuvant
PD-1/PD-L1 combined with CTLA-4 inhibitors for solid malignancies:
A systematic review and meta-analysis. World J Surg Oncol.
21(349)2023.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Willsmore ZN, Coumbe BGT, Crescioli S,
Reci S, Gupta A, Harris RJ, Chenoweth A, Chauhan J, Bax HJ, McCraw
A, et al: Combined anti-PD-1 and anti-CTLA-4 checkpoint blockade:
treatment of melanoma and immune mechanisms of action. Eur J
Immunol. 51:544–556. 2021.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Finn RS, Qin S, Ikeda M, Galle PR, Ducreux
M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, et al: Atezolizumab
plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J
Med. 382:1894–1905. 2020.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Roussot N, Fumet JD, Limagne E, Thibaudin
M, Hervieu A, Hennequin A, Zanetta S, Dalens L, Fourrier T, Galland
L, et al: A phase I study of the combination of atezolizumab,
tiragolumab, and stereotactic body radiation therapy in patients
with metastatic multiorgan cancer. BMC Cancer.
23(1080)2023.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Huang D, Ke L, Cui H and Li S: Efficacy
and safety of PD-1/PD-L1 inhibitors combined with anti-angiogenic
therapy for the unresectable hepatocellular carcinoma and the
benefit for hepatitis B virus etiology subgroup: A systematic
review and meta-analysis of randomized controlled trials. BMC
Cancer. 23(474)2023.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Park S, Kim TM, Han JY, Lee GW, Shim BY,
Lee YG, Kim SW, Kim IH, Lee S, Kim YJ, et al: Phase III, randomized
study of atezolizumab plus bevacizumab and chemotherapy in patients
with EGFR- or ALK-mutated non-small-cell lung cancer. J Clin Oncol.
42:1241–1251. 2024.PubMed/NCBI View Article : Google Scholar
|
